The 150 mg dose of solengepras (CVN424), Cerevance’s investigational oral treatment for Parkinson’s disease, significantly reduced average daily off time — periods when symptoms reappear despite medication — compared with placebo, according to topline results from a Phase 3 trial. The Phase 3 ARISE trial (NCT06553027) evaluated…
News
A real-world study found that psychiatric issues, including hallucinations and delusions, developed in some people with advanced Parkinson’s disease after they started Vyalev (foscarbidopa and foslevodopa), but most were manageable with infusion-rate adjustments or low-dose antipsychotic medications. The study, “…
The first patient has been dosed in a Phase 2a clinical trial evaluating Jotrol, an investigational oral formulation of resveratrol that Jupiter Neurosciences is developing for Parkinson’s disease. The trial is expected to be completed in the first half of 2029. The RESET trial (NCT07592767) is enrolling…
Amprion and Prema Cognition have entered into a collaboration to explore an approach for identifying and evaluating people at risk for Parkinson’s disease and related disorders that combines digital cognitive testing with molecular biomarker analysis. The partnership will pair Premas’ cognitive assessment technology, called Premaz, with…
Chemical changes in the brain region known as the cerebellum may play a key role in the cognitive issues experienced by people with Parkinson’s disease, a study found. The researchers used specialized MRI scans to track glutamate, a brain signaling molecule, and pinpoint…
The first Parkinson’s disease patient has been implanted with Newronika‘s adaptive AlphaDBS, an innovative deep brain stimulation (DBS) system, as part of a pivotal clinical trial underway in Italy. The ADVENT study (NCT06891781) will compare the adaptive AlphaDBS system with conventional DBS in people with Parkinson’s. The trial…
Blue light therapy delivered through Chrono Eyewear’s Propeaq glasses may help people with Parkinson’s disease sleep better and feel less sleepy during the day, a small study shows. After two weeks, those using blue light glasses reported greater improvements in sleep quality and daytime alertness, as well as…
Gain Therapeutics’ oral therapy candidate rexaceract, formerly called GT-02287, stabilized motor symptoms in a small group of people with Parkinson’s disease who were treated for one year. That’s according to new data from an open-label extension of an early clinical trial, which showed no meaningful progression of Parkinson’s…
People with Parkinson’s disease with REM sleep behavior disorder (RBD) showed a broader pattern of motor, psychiatric, and daily-function problems than those with insomnia or sleep apnea, according to a large database study. RBD was particularly strongly associated with slowed movement, or bradykinesia, and hallucinations, as well as difficulties…
Eight weeks of exercises designed to strengthen the arms and hands while muscles lengthen reduced tremor and improved grip strength and hand function in people with Parkinson’s disease, the results of a small randomized clinical trial show. The benefits were seen…
Recent Posts
- Having good and bad days can be confusing with Parkinson’s disease
- Mayo Clinic tests low-dose radiation to slow Parkinson’s progression
- Stem cell therapy improves motor function in Parkinson’s trial, data show
- Caring for a friend gave me insight into the challenges of being a caregiver
- Later brain stimulation linked to faster decline in some with Parkinson’s